Chronic Urticaria or Hives Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI In

Chronic Urticaria or Hives Pipeline constitutes 20+ key companies continuously working towards developing 22+ Chronic Urticaria or Hives treatment therapies, analyzes DelveInsight.

DelveInsight's "Chronic Urticaria or Hives - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in Chronic Urticaria or Hives. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.

Key Takeaways from the Chronic Urticaria or Hives Pipeline Report:

DelveInsight's Chronic Urticaria or Hives pipeline analysis highlights a robust landscape, with 20+ active players developing 22+ pipeline drugs for the treatment of Chronic Urticaria or Hives across various stages of clinical development.
On April 18, 2025, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab), developed by Sanofi and Regeneron, for the treatment of CSU in patients aged 12 years and older who are inadequately controlled with H1 antihistamines. This approval marks the first targeted therapy for CSU in over a decade, providing a new option for the estimated 300,000 U.S. patients who struggle with this condition .​
Previously, in 2023, the FDA had declined to approve Dupixent for CSU, citing the need for additional efficacy data. The resubmission included new pivotal data confirming Dupixent's efficacy, leading to the recent approval .​
Key Chronic Urticaria or Hives companies such as Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United BioPharma, Glenmark Pharmaceuticals, UCB Biopharma, GI Innovation, Celldex Therapeutics, Eli Lilly and Company, Amgen, ValenzaBio, Third Harmonic Bio, Inmagene, Lanier Biotherapeutics, and others are evaluating new drugs for Chronic Urticaria or Hives to improve the treatment landscape.
Promising Chronic Urticaria or Hives pipeline therapies in various stages of development include SYN008, Povorcitinib, Briquilimab, and others.

Chronic Urticaria or Hives Overview

Chronic urticaria (CU) is a skin condition marked by the presence of hives or welts lasting longer than six weeks, often accompanied by persistent itching and discomfort, which can significantly affect quality of life. CU may arise without a known cause (idiopathic) or may be linked to other health issues.

Uncover the latest breakthroughs in Chronic Urticaria or Hives therapeutics, download our report @ https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Urticaria or Hives Pipeline Analysis
The Chronic Urticaria or Hives pipeline insights report 2025 provides insights into:
Provides comprehensive insights into key companies developing therapies in the Chronic Urticaria or Hives Market.

Categorizes Chronic Urticaria or Hives therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Chronic Urticaria or Hives drugs under development based on:

Stage of development

Chronic Urticaria or Hives Route of Administration

Target receptor

Monotherapy vs. combination therapy

Chronic Urticaria or Hives Mechanism of Action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Chronic Urticaria or Hives Licensing Agreements

Funding and investment activities that support future advancements in the Chronic Urticaria or Hives market.

Get Full Insights into the Chronic Urticaria or Hives Pipeline and Future Market Trends - Download the Report Now: https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Urticaria or Hives Emerging Drugs

SYN008: Synermore Biologics

SYN008 is a biosimilar version of Omalizumab (Xolair), a humanized monoclonal antibody that targets immunoglobulin E (IgE). It works by binding to free IgE in the bloodstream, preventing it from interacting with immune effector cells that initiate allergic reactions, regardless of the allergen involved. Comprehensive comparability assessments have been conducted to evaluate the similarity between SYN008 and the reference drug, Omalizumab. An investigational new drug (IND) application for SYN008 was submitted to the China Food and Drug Administration (CFDA) in October 2014. A Phase I clinical trial was successfully completed in Australia in September 2016. Currently, SYN008 is in Phase III development for the treatment of chronic urticaria.

Povorcitinib: Incyte Corporation

Povorcitinib (INCB54707) is an oral, small-molecule inhibitor that selectively targets JAK1. It is currently in Phase 3 clinical development for the treatment of hidradenitis suppurativa (HS) and vitiligo, with plans underway for a Phase 3 trial in prurigo nodularis (PN). Ongoing Phase 2 studies are also evaluating its potential in PN, asthma, and chronic spontaneous urticaria. The drug is protected by compound and use patents in certain regions within its development territory. At present, povorcitinib is in Phase II of clinical development for chronic urticaria.

Briquilimab: Jasper Therapeutics

Briquilimab (JSP191) is an engineered, unconjugated antibody that targets the c-Kit receptor by preventing its interaction with its natural ligand, stem cell factor (SCF). This SCF-c-Kit signaling pathway is essential for the survival of mast cells. By inhibiting this interaction, briquilimab disrupts a key survival mechanism, leading to the programmed death of mast cells.

Chronic Urticaria or Hives Pipeline Therapeutic Assessment

Chronic Urticaria or Hives Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Chronic Urticaria or Hives By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chronic Urticaria or Hives Assessment by Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Chronic Urticaria or Hives Assessment by Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Download the Chronic Urticaria or Hives Sample Report for Key Insights on the Chronic Urticaria or Hives Treatment Market and Therapeutics: https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Chronic Urticaria or Hives Current Treatment Patterns
4. Chronic Urticaria or Hives - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Urticaria or Hives Late-Stage Products (Phase-III)
7. Chronic Urticaria or Hives Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Urticaria or Hives Discontinued Products
13. Chronic Urticaria or Hives Product Profiles
14. Chronic Urticaria or Hives Key Companies
15. Chronic Urticaria or Hives Key Products
16. Dormant and Discontinued Products
17. Chronic Urticaria or Hives Unmet Needs
18. Chronic Urticaria or Hives Future Perspectives
19. Chronic Urticaria or Hives Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Urticaria or Hives Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life Chronic Urticaria or Hivesences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.